Literature DB >> 2910912

Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate.

H J Weiss1, J Hawiger, Z M Ruggeri, V T Turitto, P Thiagarajan, T Hoffmann.   

Abstract

Platelet adhesion and thrombus formation on subendothelium, studied at a shear rate of 2,600 s-1, were inhibited by two synthetic peptides known to interact with GPIIb-IIIa. One peptide (HHLGGAKQAGDV) corresponds to the carboxyl terminal segment of the fibrinogen gamma-chain (gamma 400-411) and the other (RGDS) contains the amino acid sequence Arg-Gly-Asp (RGD) common to fibronectin, von Willebrand factor, vitronectin and the alpha-chain of fibrinogen. Neither platelet adhesion nor thrombus formation were decreased in a patient with severe congenital fibrinogen deficiency and this was equally true when his blood was further depleted of the small amounts of fibrinogen present utilizing an anti-fibrinogen antibody. In normal subjects, adhesion and thrombus formation were inhibited by the Fab' fragments of a monoclonal anti-GPIIb-IIIa antibody (LJ-CP8), which interferes with the interaction of platelets with all four adhesive proteins in both the fluid and solid phase. However, another anti-GPIIb-IIIa antibody (LJ-P5) that had minimal effects on the interaction of platelets with fibrinogen, but inhibited to varying degrees platelet interaction with other adhesive proteins, was equally effective. The findings demonstrate that, at a shear rate of 2,600 s-1, adhesive proteins other than fibrinogen are involved in GPIIb-IIIa-mediated platelet adhesion and thrombus formation on subendothelium. In addition, since LJ-P5 inhibited the binding of soluble von Willebrand factor and vitronectin, these adhesive proteins may be involved in platelet thrombus formation. In contrast to the results obtained at a shear rate of 2,600 s-1, fibrinogen could play a role in mediating platelet-platelet interactions with weak agonists or lower shear rates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910912      PMCID: PMC303673          DOI: 10.1172/JCI113871

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  86 in total

1.  Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.

Authors:  J Owen; K D Friedman; B A Grossman; C Wilkins; A D Berke; E R Powers
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

2.  The synthetic RGDS peptide inhibits the binding of fibrinogen lacking intact alpha chain carboxyterminal sequences to human blood platelets.

Authors:  E I Peerschke; D K Galanakis
Journal:  Blood       Date:  1987-03       Impact factor: 22.113

3.  Evidence that arginyl-glycyl-aspartate peptides and fibrinogen gamma chain peptides share a common binding site on platelets.

Authors:  S C Lam; E F Plow; M A Smith; A Andrieux; J J Ryckwaert; G Marguerie; M H Ginsberg
Journal:  J Biol Chem       Date:  1987-01-25       Impact factor: 5.157

4.  von Willebrand factor can substitute for plasma fibrinogen in ADP-induced platelet aggregation.

Authors:  S Timmons; J Hawiger
Journal:  Trans Assoc Am Physicians       Date:  1986

5.  Fibrinogen-independent aggregation and deaggregation of human platelets: studies in two afibrinogenemic patients.

Authors:  M Cattaneo; R L Kinlough-Rathbone; A Lecchi; C Bevilacqua; M A Packham; J F Mustard
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

6.  Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa.

Authors:  D M Peterson; N A Stathopoulos; T D Giorgio; J D Hellums; J L Moake
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

7.  Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.

Authors:  J L Moake; N A Turner; N A Stathopoulos; L H Nolasco; J D Hellums
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

8.  Increased surface expression of the membrane glycoprotein IIb/IIIa complex induced by platelet activation. Relationship to the binding of fibrinogen and platelet aggregation.

Authors:  K Niiya; E Hodson; R Bader; V Byers-Ward; J A Koziol; E F Plow; Z M Ruggeri
Journal:  Blood       Date:  1987-08       Impact factor: 22.113

9.  Rheological aspects of thrombosis and haemostasis: basic principles and applications. ICTH-Report--Subcommittee on Rheology of the International Committee on Thrombosis and Haemostasis.

Authors:  H L Goldsmith; V T Turitto
Journal:  Thromb Haemost       Date:  1986-06-30       Impact factor: 5.249

10.  Monoclonal antibodies to the glycoprotein IIb-IIIa epitopes involved in adhesive protein binding: effects on platelet spreading and ultrastructure on human arterial subendothelium.

Authors:  J B Lawrence; H R Gralnick
Journal:  J Lab Clin Med       Date:  1987-04
View more
  29 in total

Review 1.  Glycoprotein IIb/IIIa receptor inhibition in interventional cardiology.

Authors:  C M Gibson; J L Moynihan; E N Al-Mousa; M Campsey; R Gandhi; S Murphy; S Mattson; K A Ryan; R Mesley; J Swanson; M N Arshad; S J Marble
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

2.  Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen.

Authors:  H Ni; C V Denis; S Subbarao; J L Degen; T N Sato; R O Hynes; D D Wagner
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

Review 3.  The human platelet fibrinogen receptor: clinical and therapeutic significance.

Authors:  M Cahill; R Mistry; D B Barnett
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

4.  Elevation of platelet activating factor, inflammatory cytokines, and coagulation factors in the internal jugular vein of patients with subarachnoid hemorrhage.

Authors:  Y Hirashima; S Nakamura; S Endo; N Kuwayama; Y Naruse; A Takaku
Journal:  Neurochem Res       Date:  1997-10       Impact factor: 3.996

5.  Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions.

Authors:  S Goto; Y Ikeda; E Saldívar; Z M Ruggeri
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

Review 6.  von Willebrand factor.

Authors:  Z M Ruggeri
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 7.  A risk-benefit assessment of abciximab in angioplasty.

Authors:  N S Kleiman
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

8.  Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa.

Authors:  L De Marco; M Mazzucato; D De Roia; A Casonato; A B Federici; A Girolami; Z M Ruggeri
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

Review 9.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 10.  Role of cellular elements in thrombus formation and dissolution.

Authors:  N Wohner
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2008-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.